#United States #Bridgewater #Insmed #ARIKAYCE #Brinsupri

Insmed's Strong Performance and Promising Future: 2025 Financial Results

Insmed Incorporated, a leading biopharmaceutical company, has released its financial results for the fourth quarter and full year of 2025, showcasing impressive growth in revenue driven by its innovative products, BRINSUPRI (brensocatib) and ARIKAYCE (amikacin liposome inhalation suspension). The company is optimistic about continuing this trend into 2026.

2025 Financial Overview

In 2025, Insmed reported total revenues of approximately $606.4 million. Among these, BRINSUPRI generated $144.6 million in revenue during the fourth quarter alone, marking a significant entry into the market following its approval in November 2025. The full year's revenue from BRINSUPRI reached $172.7 million, reflecting a strong acceptance among patients, particularly those with non-cystic fibrosis bronchiectasis (NCFB).

ARIKAYCE also demonstrated impressive growth, with quarterly revenues of $119.2 million and annual revenue totaling $433.8 million, representing a 19% increase from the previous year. The growth of ARIKAYCE surpassed the company’s guidance, reinforcing its role as a critical component of Insmed’s portfolio.

Strategic Outlook for 2026

Insmed anticipates that BRINSUPRI will generate at least $1 billion in revenues throughout 2026, a target supported by the recent European Commission approval and anticipated regulatory decisions in the UK and Japan. The company aims to enhance the accessibility of BRINSUPRI for patients with NCFB, continuing its commitment to addressing unmet medical needs.

For ARIKAYCE, Insmed foresees revenues between $450 million to $470 million in 2026. This expectation is backed by a strong performance across various markets, highlighting Insmed’s ability to adapt and expand its product reach effectively.

As part of its strategic plan, Insmed is focused on advancing multiple clinical programs, including:

• - Completion of the Phase 3 ENCORE trial, with topline data expected in early 2026, which will inform regulatory submissions for broader usage of ARIKAYCE in MAC lung disease patients.
• - Initiation of a Phase 3 study for treprostinil palmitil (TPIP), aimed at treating pulmonary arterial hypertension (PAH), following its designation as an orphan drug by the FDA.
• - Continued progression of INS1148, a monoclonal antibody in development targeting respiratory and inflammatory diseases, with plans for clinical trials in the near future.

Investments in Innovation

With approximately $1.4 billion in cash and marketable securities at the close of 2025, Insmed is well-positioned to invest in its innovative therapy pipeline. This includes ongoing research and development aimed at expanding its therapeutic offerings and addressing chronic pulmonary and inflammatory diseases.

Insmed CEO Will Lewis expressed excitement about the opportunities ahead: _"As we close out 2025 and begin an exciting new year at Insmed, our U.S. commercial launch of BRINSUPRI continues to exceed our expectations. We are dedicated to bringing this essential medicine to patients. Our focus will remain on advancing our pipeline and meeting patient needs across various therapeutic areas._"

Conclusion

Insmed's financial results for 2025 highlight its commitment to innovation and patient care, with promising revenue projections for its flagship products. As the company prepares for a robust 2026, it reaffirms its strategy to provide groundbreaking therapies that transform patients' lives while navigating the complexities of the biopharmaceutical landscape. Investors and stakeholders can look forward to significant developments and potential growth stemming from Insmed’s ongoing efforts in 2026 and beyond.